Big Pharma Split Corp.

PRM.TO · TSX
Analyze with AI
Key StatsIncome StatementBalance SheetCash Flow
AnnualQuarterly
KMB
6/30/2025
12/31/2024
6/30/2024
12/31/2023
Assets––––
Cash & EquivalentsCA$2CA$1CA$2CA$0
Short-Term InvestmentsCA$0CA$25CA$26CA$0
ReceivablesCA$0CA$0CA$0CA$0
InventoryCA$0CA$0CA$0-CA$1
Other Curr. AssetsCA$0-CA$25CA$0CA$1
Total Curr. AssetsCA$3CA$1CA$28CA$0
Property Plant & Equip (Net)CA$0CA$0CA$0CA$0
GoodwillCA$0CA$0CA$0CA$0
IntangiblesCA$0CA$0CA$0CA$0
Long-Term InvestmentsCA$23CA$25CA$0CA$1
Tax AssetsCA$0CA$0CA$0CA$0
Other NC AssetsCA$0CA$0CA$0CA$0
Total NC AssetsCA$23CA$25CA$0CA$1
Other AssetsCA$0CA$0CA$0CA$0
Total AssetsCA$26CA$26CA$28CA$27
Liabilities––––
PayablesCA$0CA$0CA$0CA$0
Short-Term DebtCA$12CA$12CA$11CA$10
Tax PayableCA$0CA$0CA$0CA$0
Deferred RevenueCA$0CA$0CA$0-CA$10
Other Curr. Liab.CA$0CA$0CA$0-CA$0
Total Curr. Liab.CA$13CA$12CA$11CA$0
LT DebtCA$0CA$0CA$0CA$0
Deferred Rev, NCCA$0CA$0CA$0CA$0
Deferred Tax Liab, NCCA$0CA$0CA$0CA$0
Other NC Liab.CA$0CA$1CA$12CA$0
Total NC Liab.CA$0CA$1CA$12CA$0
Other LiabilitiesCA$0CA$13-CA$11CA$0
Cap. LeasesCA$0CA$0CA$0CA$0
Total LiabilitiesCA$13CA$13CA$12CA$11
Equity––––
Pref StockCA$0CA$0CA$0CA$0
Common StockCA$13CA$14CA$16CA$16
Retained EarningsCA$0CA$0CA$0CA$0
AOCICA$0CA$0CA$0CA$0
Other EquityCA$0CA$0CA$0CA$16
Total EquityCA$13CA$14CA$16CA$16
Supplemental Information––––
Minority InterestCA$0CA$0CA$0CA$0
Total Liab. & Tot. EquityCA$26CA$26CA$28CA$27
Net DebtCA$10CA$11CA$9CA$10